SCHEMBL483893

SCHEMBL483893

COc1ccc2nc(Cl)ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.68
NQO1 P15559 1/20 0.59
ALDH1A1 P00352 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2A6 P11509 1/20 0.50
GFER P55789 1/20 0.50
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
NQO2 P16083 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
EGFR P00533 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27511022 0.98 NCF1 (0.66) NCF1NQO1ALDH1A1CYP1A2CYP2A6
SCHEMBL622376 0.86 ALDH1A1 (0.56) NCF1NQO1ALDH1A1CYP1A2CYP2A6
SCHEMBL22104530 0.83 TEC (0.52) NCF1NQO1RAB9ANPC1
SCHEMBL3271562 0.82 MAOB (0.55) NCF1RAB9ANPC1SMN1; SMN2
SCHEMBL17366246 0.81 NCF1 (0.44) NCF1NQO1ALDH1A1GFERKDM4E
SCHEMBL1598487 0.81 NCF1 (1.00) NCF1NQO1ALDH1A1CYP1A2CYP2A6
SCHEMBL2323241 0.80 KMT2A (0.54) NCF1NQO1ALDH1A1KDM4EKMT2A
SCHEMBL17430137 0.80 NCF1 (0.49) NCF1NQO1ALDH1A1KMT2AL3MBTL1
SCHEMBL18024052 0.80 NCF1 (0.55) NCF1KDM4E
Hydrochloric Acid SCHEMBL27898424 0.79 NCF1 (0.96) NCF1NQO1ALDH1A1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN claimed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN claimed
CN-102985417-B Piperidin-4-yl azetidine derivatives as JAK1 inhibitors INCYTE CORP 2015-01-28 CN claimed
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN disclosed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 US disclosed
EP-4363415-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2025-12-10 EP disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 EP disclosed
CN-119403554-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 东丽株式会社 2025-02-07 CN disclosed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN disclosed
US-20240279217-A1 Heterocyclic compounds for the treatment of tuberculosis TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) 2024-08-22 US disclosed
CN-1466575-A Quinoline derivatives as anti-inflammatory agents - 2004-01-07 CN disclosed
EP-1313707-A1 QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-28 EP disclosed
US-20020082276-A1 Quinoline derivatives as anti-inflammatory agents SNYTEX (U.S.A.) LLC 2002-06-27 US disclosed
WO-2002012192-A1 QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-14 WO disclosed
EP-1087962-A4 PREPARATION OF HETEROARYL COMPOUNDS LILLY CO ELI (US) 2001-10-04 EP disclosed
EP-1087962-A1 PREPARATION OF HETEROARYL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-04-04 EP disclosed
WO-1999065896-A1 PREPARATION OF HETEROARYL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-12-23 WO disclosed
US-5814646-A TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS ELI LILLY AND COMPANY (US) 1998-09-29 US disclosed
US-5624937-A TREATMENT OF ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1997-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279217-A1 Heterocyclic compounds for the treatment of tuberculosis SDHA, NQO1, FNTB NCF1 1333/4885NQO1 2/4885ALDH1A1 568/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 NCF1 1182/4885NQO1 504/4885ALDH1A1 2086/4885
US-20020082276-A1 Quinoline derivatives as anti-inflammatory agents CNR1, CNR2, PTGER4 NCF1 346/4885NQO1 37/4885ALDH1A1 633/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 NCF1 1738/4885NQO1 329/4885ALDH1A1 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.